Parenteral nutrition (PN) is the treatment of choice for nutritional support of patients undergoing allo-SCT following myeloablative conditioning (MAC). Here we prospectively assessed the outcomes of early enteral nutrition (EN) in a paediatric cohort. From 2003 to 2010, all 65 consecutive children undergoing MAC allo-SCT at our referral centre began EN the day after transplantation. Post-transplant and nutritional outcomes of patients receiving only EN (EN group, n ¼ 50) were compared with those of patients requiring additional PN (EN-PN group, n ¼ 15). In the EN group time to platelet recovery (P ¼ 0.01) and length of hospitalisation (Po0.001) were shorter, while in the EN-PN group the proportion of unrelated donors (P ¼ 0.02) and the frequency of severe acute GVHD (aGVHD; P ¼ 0.004) were higher. All patients were alive at day 100. PN was started 14 days after transplant because of poor digestive tolerance to EN or severe gut aGVHD. The body mass index Z-score in the EN-PN group decreased from transplant to discharge (P ¼ 0.02). In only 23% of cases was PN required for severely ill patients. Our results suggest that EN might be considered to be an option for nutritional support in children undergoing MAC allo-SCT, while PN should be used only as a rescue option, possibly in combination with EN.
INTRODUCTION
Allo-SCT following myeloablative conditioning (MAC) in children is a toxic procedure requiring intensive nutritional support. 1, 2 Oral intake in the early post-transplant period is decreased because of vomiting, anorexia, mucositis and diarrhea due to radiochemotherapy used for conditioning. 1 --3 Complications such as infections and acute GVHD (aGVHD) add to catabolic bodily demands and impaired nutritional status, thereby increasing treatment-related adverse reactions. 1, 2, 4, 5 Parenteral nutrition (PN) is considered the method of choice for nutritional support of patients undergoing MAC allo-SCT. 6 --9 However, in light of PN-related complications (sepsis, metabolic and hepatic disorders, and gut mucosal atrophy), few teams have proposed enteral nutrition (EN) as the first feeding option after SCT. 8,10 --15 Between 2001 and 2003, we conducted a pilot study in which EN was offered early on to all adults and children who underwent MAC allo-SCT. 14 Early EN appeared to be safe and effective for feeding patients, and positively influenced both survival and aGVHD incidence. Thus, it has been used since 2003 at our referral centre for MAC allo-SCT children.
The aim of this prospective study was to analyse the outcome of systematic early EN in a paediatric population that had undergone MAC allo-SCT.
MATERIALS AND METHODS Patients
From April 2003 to December 2010, all patients under 18 years of age who underwent a MAC allo-SCT at the referral centre of Lille University Hospital, France were enrolled in this study. Most patients were treated for acute leukaemia, but patients with non-malignant haemopathies such as haemoglobinopathies and myelodysplasia were also included. The study was conducted according to our institutional guidelines. Patients and/or parents provided informed written consent to allow clinical data from their medical files to be used for research purposes.
Transplantation procedure
Patients under 2 years of age or with AML in first CR received 16 single weight-adjusted doses of CY 200 mg/kg and BU. Patients over the age of 2 with AML in second CR or with ALL were conditioned using CY 120 mg/kg and 12 Gy fractionated TBI. All patients received cyclosporine with or without short-course MTX to prevent aGVHD.
Patients had identical siblings, matched unrelated or mismatched unrelated donors. Most patients received BM or cord blood; several patients received PBSCs. Their CMV status and sex mismatch were analysed in the donor choice.
Patients were treated in HEPA-filtered rooms. Infection prophylaxis was given from day 9 before allo-SCT to the time of the patient's discharge, and it consisted of oral fluconazole, acyclovir and broad-spectrum nonabsorbable antibiotics (amphotericin B). Cotrimoxazole was delivered by mouth or tube feeding, from 9 days before transplant to the day of transplant, and then recommenced at neutrophil recovery. Febrile neutropenic patients were treated by empiric broad-spectrum i.v. antibiotics. Patients received i.v. heparin (100 IU/kg) until engraftment to prevent veno-occlusive disease.
Nutritional support
During an individual pretransplantation interview, information on nasogastric tube feeding was given. Some patients had already received transitory EN for several days before this procedure. EN was presented as part of the MAC allo-SCT procedure. Patients were urged to eat, ad libitum, a low microbial strict oral diet for as long as possible. A 5 --8-Fr polyurethane nasogastric tube was placed the next day after allo-SCT and EN was delivered overnight, using a peristaltic pump. Energy requirements were calculated according to age and sex. Isoenergetic (1 kcal/ml) and hyperenergetic (1.5 kcal/ml) EN formulae were gradually increased, depending on the patient's tolerance level, so as to reach 50 --70% of the energy requirement within 5 days. This was increased to 100% when oral feeding was impossible. Vomited tubes were promptly replaced. In case of poor tolerance (repeated vomiting, severe diarrhoea, patient refusal) or grade III --IV gut GVHD, PN was either combined with EN or replaced by it. Parenteral solutions supplemented with micronutrients included hospital custom-compounded mix for patients weighing o30 kg and commercial ready-to-use multichamber bags for the others.
Transplantation outcome
From transplantation to discharge, the incidents of events and complications were recorded as follows: neutrophil and platelet engraftments defined as 3 consecutive days with a count X0.5 Â 10 9 /l and 7 consecutive days with a count X50 Â 10 9 /l, respectively; viral and bacterial infections; mucositis and need for opioid analgesia; and aGVHD was diagnosed on the basis of clinical symptoms and/or biopsies of skin, oral mucosa, liver and gut, and graded from 0 to IV according to the Seattle criteria. 16, 17 Overall survival was assessed on day 100 after transplantation.
Nutritional assessment and blood tests EN tolerance and reasons for PN were noted. Body weight was recorded weekly from the day of transplant (day 0) to the day of discharge. Effectiveness of EN was assessed by body mass index (BMI), Z-score and body weight variation was expressed in percent of change from the day of transplant. Z-score defined as s.d. from the mean of a standard population, was calculated using French growth standards. 18 Normal nutritional status was then defined as a Z-score between À2.0 and þ 2.0 s.d. Full blood count, urea, creatinine and electrolytes tests were performed daily, and liver function tests like albuminaemia, phosphataemia, and magnesaemia were done twice a week.
Statistics
Comparisons between qualitative variables were performed using the Chi-square test (for sample 410), Yates correction (for sample between 5 and 10) and Fisher exact test (for sample o5). Quantitative data expressed in median with range were compared using a non-parametric Mann Whitney U test. The BMI Z-score during admission and discharge of each group was compared with a Wilcoxon rank sum test for paired data. The comparison of time evolution of the BMI Z-score according to the two groups was investigated by a linear mixed model using the Conover method. All tests were two-tailed and po0.05 was considered statistically significant.
RESULTS
Sixty-five consecutive patients were included: 77% (n ¼ 50) received EN only (EN group) and 23% (n ¼ 15) received both EN and PN (EN-PN group). Initial characteristics of patients and transplantation modalities are summarised in Table 1 . Compared to the EN group, patients in the EN-PN group more frequently had an unrelated donor, with trends toward higher sex-mismatched frequency and toward being older (P ¼ 0.07).
Time to neutrophil recovery was not different between groups, but both times to platelet recovery and length of hospitalisation Enteral nutrition for nutritional support in children S Azarnoush et al were shorter in the EN group. In the EN-PN group, aGVHD was more frequent and more severe, particularly in terms of gut manifestations. There was no death reported during the 100-day period following allo-SCT (Table 2 ). All patients started EN the day after allo-SCT; PN, when required, was begun 14 days later. No bleeding or infections related to the nasogastric tube placement were observed; specifically, there were no cases of epistaxis or sinusitis secondary to EN. PN was indicated because of: (a) poor gut intolerance (vomiting, insufficiency of EN volume delivered) in eight patients, including two who refused tube replacement after two extrusions by vomiting and one with acute pancreatitis; (b) severe grade III --IV gut aGVHD in six patients in whom EN was stopped; (c) acute respiratory distress syndrome unrelated to EN in one patient.
Body weight and BMI Z-score were not significantly higher, but hypoalbuminaemia and hypophosphataemia were more frequent in the EN-PN group compared with the EN group ( Table 2) . From the day of transplant to discharge, the BMI Z-score decreased in the EN-PN group from þ 0.3 (À3; 2.8) to À0.2 (À2.1; 2.5) (P ¼ 0.02). However, there was no difference in the BMI Z-score between the EN and EN-PN groups in terms of temporal evolution during hospitalisation (Figure 1 ). Five patients lost more than 10% of their initial body weight, one from the EN-PN group who had acute respiratory distress syndrome and four from the EN group. In the latter group, two patients poorly tolerated EN, whereas two others showed satisfactory tolerance to EN, but it was stopped 4 and 5 days before discharge. Daily EN intake represented 57% and 35% of the caloric requirement, respectively.
DISCUSSION
To the best of our knowledge, this is the largest cohort assessing the effectiveness of early systematic EN in children undergoing MAC allo-SCT. Our results confirm that EN is feasible and well tolerated, as 77% of the patients required no PN during the posttransplant period, no deaths occurred and the frequency of aGVHD was low. However, it showed that patients with unrelated Figure 1 . Median BMI Z-score during hospitalisation in the EN and EN-PN groups. There was no significant time evolution in the BMI Z-score between the EN group and the EN-PN group from transplantation to discharge (Conover method).
donors and, consequently, with higher risk of aGVHD were candidates for delayed PN. Independently of gut intolerance and digestive symptoms, which occurred in 23% of patients under EN, the need for PN seemed to be associated with more severely ill patients, as suggested by their longer length of stay, higher frequency of aGVHD and aggravation of nutritional status at discharge in the EN-PN group. In 2006, the European Society for Clinical Nutrition and Metabolism (ESPEN) did not recommend EN and preferred PN in SCT patients because of no proven effects upon the tumour response to treatment, therapy-associated side effects, graft survival, aGVHD and overall survival. 9 In 2009, despite successful use of EN, the ESPEN recommended that PN should be reserved for SCT patients with severe mucositis, ileus or intractable vomiting. 5 That same year, a Cochrane review confirmed PN as the first choice in preventing malnutrition in these patients despite a recognised increased risk of infection, and presented EN as an alternative in the absence of data necessary to properly compare PN with EN. 19 Therefore, Szeluga et al. 15 conducted a randomised trial comparing 31 PN with 30 EN cases in allo-and auto-SCT patients above 10 years of age; they concluded that PN was no more effective than EN, and suggested that it should be reserved for patients demonstrating intolerance to EN. Three paediatric studies concluded that EN was an effective nutritional support in SCT: Langdana et al. 10 and Papadopoulou et al.
12
studied EN (49 and 21 patients, respectively) in both allo-and auto-SCT children, while Hopman et al. 13 compared 12 EN vs 22 PN cases in allo-SCT children. However, most studies included only a small number of patients or a heterogeneous patient population of paediatric and adult patients with solid tumours, haematological malignancies, and both auto-and allo-SCT. 8 --10,15,20 Patient outcome was consistent with our pilot study conducted before 2003 comparing 22 EN vs 23 PN cases in allo-SCT patients from 4 to 53 years of age; in that study, patients who received EN less often developed severe aGVHD, while the absence of EN adversely influenced 100-day OS.
14 In our current exclusive paediatric study, TRM at day 100 was 0%, compared to 2 --12% in the literature. 21 --24 Consequently, there was no early infectionrelated mortality, the frequency of which was higher in the PN group than in the EN group in our pilot study.
14 EN might preserve gut trophicity, support the barrier function of the gut and thereby reduce the risk of bacterial translocation. 25 --31 In paediatric patients treated for malignancies, EN has a trophic effect on the gut, and continuation of nasogastric feeding during the period of maximal gut toxicity may accelerate healing. 31 Moreover, there were no complications associated with the placement of the enteral feeding tube, such as epistaxis or sinusitis. Conversely, in critically ill patients, PN has been associated with mucosal atrophy and an increased risk of infectious complications. 28 In a surgery population, PN was independently associated with an increased prevalence of bacterial translocation. 29 PN was also associated with an increased risk of line infections and metabolic disturbances such as hyperglycaemia and hypertriglyceridaemia, cholestatic liver disease and fluid overload state. 5, 20, 32 PN potentiates hepato-biliary disorders that may contribute to cholestasis due to sepsis, drug toxicity and veno-occlusive disease in allo-SCT patients. 13, 33 The low frequency of aGVHD, and particularly its gut manifestations, suggests that EN started early may decrease both its incidence and severity. In a study of 231 allo-SCT patients receiving PN, Mattsson et al. 34 found that poor oral nutrition after allogeneic SCT correlated with severe aGVHD. In the latter study, a period of over 9 days with no oral intake was associated with a high risk of grade III --IV aGVHD. However, severe grade and gut aGVHD were obstacles to EN efficiency, and constituted per se an indication for PN. Nonetheless, this did not signify failure of early EN; indeed, in the EN-PN group, patients were at greater risk of aGVHD because they more often had had an unrelated donor and a tendency toward sex mismatch than in the EN group. Likewise, significantly more patients received BM in the EN group, while more patients received cord blood in the EN-PN group, which suggests that the stem cell source responsible for longer engraftment and immune recovery (higher risk patients before transplant) could predict factors for PN. On the other hand, Cetin et al. 35 reported that delayed platelet engraftment could be related to PN.
Although mucositis has been considered to be an obstacle to successful EN, neither the incidence of severe oral mucositis, comparable in the two groups, nor TBI seemed to be predictive factors of a need for PN. As in Langdana 10 and Hopman's 13 studies, this confirmed that TBI was not a factor associated with EN intolerance. As reported in our previous study, feeding tube insertion at day 1 post transplant, following induction chemoradiation but before mucositis onset, guaranteed satisfactory tolerance. 14 The number of patients who had experienced enteral feeding before the study was comparable in the two groups. The success of an EN program also depends on the active participation of nurses, physicians and patients. At the beginning of our EN program, we faced opposition from caregivers, who felt that EN was too aggressive.
14 An EN program must be supported by a committed team (nurses, gastroenterologist and dieticians).
10,14 It should be noted that patients in the EN-PN group patients tended to be older than the others, suggesting that teenagers are reluctant to embark on such a regimen. In the Hopman study, 13 tolerance was significantly better in younger patients (mean age 3.3 vs 8 years of age). During the pre-transplant interview, emphasis was placed on EN as being a recommended essential treatment.
Papadopoulou et al. 12 found positive correlations between the duration of EN and both an increase in body weight and mild arm circumference. In Langdana's study, 86% of children were maintained exclusively on EN, with a mean percentage ideal body weight at discharge of 97%. 10 In the present study, 92% of patients maintained satisfactory nutritional status, and lost less than 10% of their body weight from transplant to discharge. But malnutrition may have been underestimated in the EN-PN group, as two-thirds of patients had hypoalbuminaemia usually associated with oedema. Despite this fact, in the latter group, both body weight and BMI Z-score decreased significantly from the day of transplant to discharge, indicating that PN was not more effective than EN in severely ill patients. Conversely, the four patients who lost X10% of their body weight in the EN group would have benefitted from combined administration of EN and PN, as EN alone was insufficient to avoid malnutrition.
This paediatric cohort, despite its limitations due to an absence of data on children under 4 transplanted in another centre, supports the fact that EN, despite gut toxicity related to the conditioning regimen and gut aGVHD, constitutes a physiological means of delivering nutrition, which might lessen morbidity and mortality, as well as cost.
10 --13, 15 We thus conclude that early enteral tube feeding might be considered as a first option in the nutritional support of children undergoing MAC allo-SCT, while PN should be used only as a rescue option and, when possible, in combination with EN.
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